Abstract: A liquid ion exchange process for recovering a concentrated purified aqueous solution of a camphorsulfonic acid salt from a dilute impure solution of the same wherein the ion exchange medium is a liquid secondary amine and the pH of the mixture during the ion exchange is maintained at 3 - 6 by treating the mixture with a polyprotic acid having two pKs of less than 2.5.

Abstract: A dosing schedule for Disodiumcromoglycate and Disodiumcromoglycate biologues whereby a substantially smaller dosage is required to bring about effective allergy inhibition. Compositions are also provided.

Abstract: A new method for preparing cytosine arabinoside involving the cyanovinylation of the aminooxazoline of D-arabinose by cis-.beta.-[trimethylammonium]-acrylonitrile tosylate. Also included are new preparations of the aminooxazoline of D-arabinose and the anion of cis-1-cyano-2-hydroxyethylene.

Abstract: It has now been discovered that novel compounds of Formula 1 are useful in the prophylactic treatment of sensitized humans and animals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature. Additionally, the compounds are formulated with pharmaceutical carriers for oral, parenteral, inhalation, or rectal means of administration.

Abstract: Novel compounds of (I) ##STR1## are useful in the prophylactic treatment of sensitized humans and animals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature. The compounds are formulated with pharmaceutical carriers for oral, parenteral, inhalation or rectal means of administration.

Abstract: Compounds of the formula ##STR1## where R.sub.4 X is a polycyclocoupled group and R.sub.1 and R.sub.2 are H or simple hydrocarbon and R.sub.3 has the same value and additionally simple acyl, can be made by a variety of syntheses. They have hypolipedemic and antiatherosclerotic properties, and are useful in that field.

Abstract: A process for preparing a 2-R.sub.3 -3-(cyanoimino)-3-(amino)propionitrile which comprisesA. reacting a mineral acid addition salt of a 2-cyanoacetimidate of the formula ##STR1## with cyanamide in an organic solvent to form a N,2-dicyanoacetimidate B. REACTING A N,2-dicyanoacetimidate of the formula ##STR2## with an amine of the formula ##STR3## to form a 2-R.sub.3 -3-(cyanoimino)propionitrile of the formula ##STR4## N,2-dicyanoacetimidate compounds are claimed as well.

Abstract: It has now been discovered that novel compounds of the figure below and their pharmaceutical compositions are useful in the prophylactic treatment of sensitized humans and animals for allergy and anaphylactic reactions of a reagin or non-reagin mediated nature.

Abstract: Animals, especially birds and murine pests, are repelled by .gamma.- or .omega.-amino-.alpha.,.alpha.-diphenylalkanoamides, their acid addition and quaternary ammonium salts, their N-oxides, and acid addition salts of the N-oxides. The active agents can be coated on grains in order to repel animals especially birds. Animal pest damage to mature crops for harvest and newly planted seeds is prevented.

Abstract: Novel hydrogenated pyrimidine nucleosides and nucleotides are produced by catalytic hydrogenation, particularly in the presence of a rhodium catalyst. The novel compounds are specifically used to inhibit deaminating enzymes, which would inactivate cytosine arabinoside by conversion to uridine arabinoside. Cytosine arabinoside is used for its anti-viral, particularly anti-herpes and anticytotoxic activity in mammals and birds, as well as to destroy phages which interfere with the production of antibiotics. Novel formulations containing cytosine arabinoside and the hydrogenated pyrimidine nucleosides are advantageous to provide prolonged cytosine arabinoside effects.

Abstract: Novel steroid derivatives containing a tyrosine ester amide group linked to an 11-hydroxysteroid alkylene dicarboxylic hemi-ester are described, suitable for iodination with radioactive iodine, useful in radioimmunoassay.

Abstract: The administration of 25-hydroxycholecalciferol, 24,25-dihydroxycholecalciferol, 25,26-dihydroxycholecalciferol, 1,25-dihydroxycholecalciferol, 25-hydroxydihydrotachysterol.sub.3, 25-hydroxyergocalciferol, 1-.alpha.-hydroxycholecalciferol, and their acylates to hens increases the thickness of the egg shells. Composition and methods are provided.

Abstract: Compounds of the formula below are useful in the prophylactic treatment of sensitized humans and animals for allergy and anaphylactic reactions of a reagin or non-reagin mediated nature. The compounds are formulated with pharmaceutical carriers for administration.

Abstract: 2-(1,3-Diaza-2-cycloalken-2-ylamino)quinazolines and substituted compounds are compounded into local and topical compositions for the treatment of viruses.

Abstract: In accordance with this invention, there are disclosed compounds of the formula ##STR1## wherein X is selected from the group consisting of nitro and amino with the proviso that when Y is hydrogen, X is nitro; Y is selected from the group consisting of hydrogen and fluoro; R is selected from the group consisting of hydrogen and alkyl of from one to six carbon atoms, inclusive.These compounds are compounded into pharmaceutical compositions and administered to mammals for purposes of relieving inflammation and to mammals in need of prophylactic anti-thrombotic treatment.

Abstract: A method of improving the endogenous production of prostaglandins by a mammal is disclosed, which comprises administering to the mammal an effective amount of 1-pyridylalkyl-3-naphthyl-2(thio)ureas. Disclosed also are novel substituted 1-pyridylalkyl-3-naphthyl-2(thio)ureas and therapeutic compositions thereof which are useful in carrying out the method of the invention.Disclosed also are methods of treating mammals for clinical conditions responsive to prostaglandins, such as, for example, male infertility, epidermal injuries, atonic uterine bleeding, thromboembolic disease and like clinical conditions.

Abstract: A composition which comprises a substance which is a substituted aromatic and which inhibits the thrombotic or clotting activity of a material, chemically bonded through an --N=N-- grouping to a second aromatic which is chemically bonded at a sulfonyl grouping through a nitrogen containing chemical bond to a material which is susceptible to interaction with a nitrene.

Abstract: Novel compounds of FIG.

Abstract: A method of improving the endogenous production of prostaglandins by a mammal is disclosed, which comprises administering to the mammal an effective amount of certain 1-pyridylalkyl-3-phenylureas. Disclosed also are novel substituted 1-pyridylalkyl-3-phenylureas and therapeutic compositions thereof which are useful in carrying out the method of the invention.Disclosed also are methods of treating mammals for clinical conditions responsive to prostaglandins, such as, for example, male infertility, epidermal injuries, atonic uterine bleeding, thromboembolic disease and like clinical conditions.

Abstract: A method for preparing 9.beta., 10.alpha.-cholesta-5,7-diene-3.beta.,25 diol and 25-hydroxyprevitamin D.sub.3 by irradiation.